Hannover Unified Biobank
Hannover Unified Biobank is recorded as a service provider in 7 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 7 of 7 trials · Latest update first
NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan+pembrolizumab vs. SoC chemotherapy in clinical stage II-III, triple-negative early breast cancer (ADAPT-TN-IV)
Sponsor WSG Women's Cancer Study Group GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Adjuvant Dynamic marker - adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk, HR+/HER2- early breast cancer (ADAPTcycle)
Sponsor WSG Women's Cancer Study Group GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/or clinically high-risk ER+/HER2- early breast cancer (ADAPTela)
Sponsor WSG Women's Cancer Study Group GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab in low-risk, triple-negative early breast cancer (ADAPT-TN-III)
Sponsor WSG Women's Cancer Study Group GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
An interventional, open-label, phase III study to evaluate the safety, efficacy, and impact on quality of life of capivasertib alongside standard-of-care endocrine treatment in patients with HR+/HER2- advanced breast cancer and progression on prior endocrine-based treatment (CAPIcorn)
Sponsor WSG Women's Cancer Study Group GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+pertuzumab in HER2+ early breast cancer (ADAPT-HER2-IV)
Sponsor WSG Women's Cancer Study Group GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) intermediate to high risk, HR+/HER2- early breast cancer (ADAPTlate)
Sponsor WSG Women's Cancer Study Group GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Hannover Unified Biobank?
The 2026-10-09 snapshot links Hannover Unified Biobank to 7 distinct CTIS trials. Recorded services include Future Biomedical Research, Storage biological samples. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Hannover Unified Biobank?
The most frequently recorded therapeutic areas are Solid Tumor Oncology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Hannover Unified Biobank conducted?
The linked trials record locations in 6 countries, including Germany, Spain, Poland, Austria, Belgium. These are trial locations, not confirmed office locations or countries where Hannover Unified Biobank delivered services.
What can this page tell me about Hannover Unified Biobank's trial experience?
Browse 7 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Hannover Unified Biobank. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Hannover Unified Biobank